Data Insights

Cobimetinib fumarate by F. Hoffmann-La Roche for Peritoneal Cancer: Likelihood of Approval

Cobimetinib fumarate is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Peritoneal Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Cobimetinib Fumarate in Peritoneal Cancer

Data Insights

Cobimetinib fumarate by F. Hoffmann-La Roche for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval

Cobimetinib fumarate is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Human Epidermal Growth Factor...

Likelihood of Approval and Phase Transition Success Rate Model - Cobimetinib Fumarate in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer)

Data Insights

Cobimetinib fumarate by F. Hoffmann-La Roche for Metastatic Breast Cancer: Likelihood of Approval

Cobimetinib fumarate is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Metastatic Breast Cancer. According...

Likelihood of Approval and Phase Transition Success Rate Model - Cobimetinib Fumarate in Metastatic Breast Cancer

Data Insights

Cobimetinib fumarate by F. Hoffmann-La Roche for Fallopian Tube Cancer: Likelihood of Approval

Cobimetinib fumarate is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Fallopian Tube Cancer. According...

Likelihood of Approval and Phase Transition Success Rate Model - Cobimetinib Fumarate in Fallopian Tube Cancer

Data Insights

Cobimetinib fumarate by F. Hoffmann-La Roche for Neuroblastoma: Likelihood of Approval

Cobimetinib fumarate is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Neuroblastoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Cobimetinib Fumarate in Neuroblastoma

Data Insights

Cobimetinib fumarate by F. Hoffmann-La Roche for Craniopharyngioma: Likelihood of Approval

Cobimetinib fumarate is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Craniopharyngioma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Cobimetinib Fumarate in Craniopharyngioma

Data Insights

Cobimetinib fumarate by F. Hoffmann-La Roche for Relapsed Acute Myeloid Leukemia: Likelihood of Approval

Cobimetinib fumarate is under clinical development by F. Hoffmann-La Roche and currently in Phase I for Relapsed Acute Myeloid Leukemia....

Likelihood of Approval and Phase Transition Success Rate Model - Cobimetinib Fumarate in Relapsed Acute Myeloid Leukemia

Data Insights

Cobimetinib fumarate by F. Hoffmann-La Roche for Refractory Acute Myeloid Leukemia: Likelihood of Approval

Cobimetinib fumarate is under clinical development by F. Hoffmann-La Roche and currently in Phase I for Refractory Acute Myeloid Leukemia....

Likelihood of Approval and Phase Transition Success Rate Model - Cobimetinib Fumarate in Refractory Acute Myeloid Leukemia